Analyst Price Targets — PYXS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 18, 2025 7:36 pm | Leonid Timashev | RBC Capital | $5.00 | $1.73 | StreetInsider | Pyxis Oncology Inc. (PYXS) PT Lowered to $5 at RBC Capital |
| November 24, 2025 12:31 pm | Sudan Loganathan | Stephens | $8.00 | $4.80 | TheFly | Pyxis Oncology price target raised to $8 from $5 at Stephens |
| November 4, 2025 11:35 am | Bradley Canino | Guggenheim | $7.00 | $3.81 | StreetInsider | Pyxis Oncology Inc. (PYXS) PT Raised to $7 at Guggenheim |
| September 4, 2025 9:40 am | — | Guggenheim | $5.00 | $1.61 | TheFly | Pyxis Oncology initiated with a Buy at Guggenheim |
| August 16, 2024 6:46 am | Swayampakula Ramakanth | H.C. Wainwright | $7.00 | $3.52 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Pyxis Oncology Inc. (PYXS) |
| August 7, 2024 4:23 pm | Bradley Canino | Stifel Nicolaus | $10.00 | $3.13 | TheFly | Pyxis Oncology initiated with a Buy at Stifel |
| May 7, 2024 7:32 am | Farzin Haque | Jefferies | $10.00 | $4.31 | StreetInsider | Jefferies Assumes Pyxis Oncology Inc. (PYXS) at Buy |
Latest News for PYXS
Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026
Pyxis Oncology (NASDAQ: PYXS - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect Pyxis Oncology to announce earnings of ($0.35) per share for the quarter. Parties may visit the the company's upcoming Q4 2025 earning results page for the latest details on the
Shares of Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PYXS.
U.S. House Trading
No House trades found for PYXS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.